AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Go back to AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata| AbbVie (NYSE: ABBV) | Delayed: 249.95 -6.51 (2.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $256.46 | 52 Week High | $68.12 | |||
| Open | $251.84 | 52 Week Low | $50.71 | |||
| Day High | $254.62 | P/E | 54.22 | |||
| Day Low | $248.86 | EPS | $4.61 | |||
| Volume | 1,062,110 | |||||
